Literature DB >> 22106869

Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.

Dawn Buse1, Aubrey Manack, Daniel Serrano, Michael Reed, Sepideh Varon, Catherine Turkel, Richard Lipton.   

Abstract

BACKGROUND: The Headache Impact Test-6 (HIT-6) has been demonstrated to be a reliable and valid measure that assesses the impact of headaches on the lives of persons with migraine. Originally used in studies of episodic migraine (EM), HIT-6 is finding increasing applications in chronic migraine (CM) research.
OBJECTIVES: (1) To examine the headache-impact on persons with migraine (EM and CM) using HIT-6 in a large population sample; (2) to identify predictors of headache-impact in this sample; (3) to assess the magnitude of effect for significant predictors of headache-impact in this sample.
METHODS: The American Migraine Prevalence and Prevention study is a longitudinal, population-based study that collected data from persons with severe headache from 2004 to 2009 through annual, mailed surveys. Respondents to the 2009 survey who met International Classification of Headache Disorders 2 criteria for migraine reported at least 1 headache in the preceding year, and completed the HIT-6 questionnaire were included in the present analysis. Persons with migraine were categorized as EM (average <15 headache days per month) or CM (average ≥15 headache days per month). Predictors of headache-impact examined include: sociodemographics; headache days per month; a composite migraine symptom severity score (MSS); an average pain severity rating during the most recent long-duration headache; depression; and anxiety. HIT-6 scores were analyzed both as continuous sum scores and using the standard, validated categories: no impact; some impact; substantial impact; and severe impact. Group contrasts were based on descriptive statistics along with linear regression models. Multiple imputation techniques were used to manage missing data.
RESULTS: There were 7169 eligible respondents (CM = 373, EM = 6554). HIT-6 scores were normally distributed. After converting sum HIT-6 scores to the standard categories, those with CM were significantly more likely to experience "severe" headache impact (72.9% vs 42.3%) and had higher odds of greater adverse headache impact compared with persons with EM (OR = 3.5, 95% CI = 2.77-4.41, P < .0001). Significant predictors of adverse headache impact in both groups included younger age, higher MSS score, higher average long-duration headache pain severity rating, and depression. Lower annual household income, anxiety, and higher standardized headache day frequency predicted adverse headache impact in EM but not CM. With few exceptions, gender, race, and body mass index did not significantly predict adverse headache impact. Finally, rates of depression were more than double among persons with CM (CM = 25.2%, EM = 10.0%), and rates of anxiety were nearly triple (CM = 23.6%, EM = 8.5%).
CONCLUSIONS: This work further establishes HIT-6 as a useful instrument for characterizing CM and understanding the increased disease related burden. Persons with CM had significantly higher odds of greater adverse headache impact, when compared with EM. Predictors of greater headache impact for both groups included higher MSS scores, higher average headache pain severity, and depression. Additional predictors unique to EM included higher average household income, younger age, higher standardized headache day frequency, and anxiety. This finding may be related to differences in sample size and power. Further exploration is warranted.
© 2011 American Headache Society.

Entities:  

Mesh:

Year:  2011        PMID: 22106869     DOI: 10.1111/j.1526-4610.2011.02046.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  61 in total

1.  Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

Authors:  L M Bloudek; M Stokes; D C Buse; T K Wilcox; R B Lipton; P J Goadsby; S F Varon; A M Blumenfeld; Z Katsarava; J Pascual; M Lanteri-Minet; P Cortelli; P Martelletti
Journal:  J Headache Pain       Date:  2012-05-29       Impact factor: 7.277

2.  Altered brainstem auditory evoked potentials in a rat central sensitization model are similar to those in migraine.

Authors:  Xianghong Arakaki; Gary Galbraith; Victor Pikov; Alfred N Fonteh; Michael G Harrington
Journal:  Brain Res       Date:  2014-03-27       Impact factor: 3.252

3.  Complementary and conventional medicine use among youth with recurrent headaches.

Authors:  Christina Bethell; Kathi J Kemper; Narangerel Gombojav; Thomas K Koch
Journal:  Pediatrics       Date:  2013-10-14       Impact factor: 7.124

4.  Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial.

Authors:  Elizabeth K Seng; Alexandra B Singer; Christopher Metts; Amy S Grinberg; Zarine S Patel; Maya Marzouk; Lauren Rosenberg; Melissa Day; Mia T Minen; Richard B Lipton; Dawn C Buse
Journal:  Headache       Date:  2019-09-26       Impact factor: 5.887

Review 5.  How Well Does the ICHD 3 (Beta) Help in Real-Life Migraine Diagnosis and Management?

Authors:  Sait Ashina; Jes Olesen; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2016-12

Review 6.  Headache and Its Management in Patients With Multiple Sclerosis.

Authors:  Farhat Husain; Gabriel Pardo; Meheroz Rabadi
Journal:  Curr Treat Options Neurol       Date:  2018-03-24       Impact factor: 3.598

7.  Episodic and Chronic Migraine in Primary Care.

Authors:  Nathan P Young; Lindsey M Philpot; Robert A Vierkant; Jordan K Rosedahl; Sudhindra G Upadhyaya; Ann Harris; Jon O Ebbert
Journal:  Headache       Date:  2019-04-29       Impact factor: 5.887

8.  Can weight loss improve migraine headaches in obese women? Rationale and design of the Women's Health and Migraine (WHAM) randomized controlled trial.

Authors:  Dale S Bond; Kevin C O'Leary; J Graham Thomas; Richard B Lipton; George D Papandonatos; Julie Roth; Lucille Rathier; Richard Daniello; Rena R Wing
Journal:  Contemp Clin Trials       Date:  2013-03-22       Impact factor: 2.226

Review 9.  Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults.

Authors:  Simon Law; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-20

10.  Psychosocial difficulties in patients with episodic migraine: a cross-sectional study.

Authors:  Alberto Raggi; Venusia Covelli; Silvia Schiavolin; Ambra M Giovannetti; Milda Cerniauskaite; Rui Quintas; Matilde Leonardi; Carla Sabariego; Licia Grazzi; Domenico D'Amico
Journal:  Neurol Sci       Date:  2016-09-09       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.